SANTA CLARA, Calif., Oct. 18 /PRNewswire/ -- Abmaxis, Inc., a privately held biopharmaceutical company, today announced that it has achieved a major milestone under its collaboration agreement with Merck & Co., Inc. Under the terms of the agreement, Abmaxis was to optimize an undisclosed Merck human monoclonal antibody for potential therapeutic use. The Abmaxis team has successfully re-engineered Merck's human monoclonal antibody and improved antibody affinity more than 70-fold while retaining its specificity, triggering a milestone payment from Merck.
"It has been a rewarding experience for the Abmaxis team to work with Merck on this technically challenging project and this achievement demonstrates the advantages of our Abmaxis in-silico Immunization (AISIM(TM)) technology platform over conventional antibody engineering technologies," said Peter Luo, Ph.D., Chief Technology Officer of Abmaxis.
"The results we were able to achieve for Merck are an important validation of our structure-centric approach towards antibody engineering," added Shirley Clayton, President and Chief Executive Officer. "It would be a challenge to the conventional sequence-centric antibody engineering approach to achieve such a significant improvement."
Abmaxis, Inc. is a privately held biopharmaceutical company located in Santa Clara, California. It is dedicated to the discovery, optimization and development of monoclonal antibody (MAb) products for human therapeutics and diagnostics. The company has a seasoned management team with experience in the biotech, pharmaceutical and life science industries. Abmaxis has developed and validated a breakthrough antibody engineering technology platform, Abmaxis in-silico Immunization (AISIM(TM)), which is used for building an internal product pipeline and for collaborations with global biotech and pharmaceutical partners. The product strategy is to develop a pipeline of products with a spectrum of risk profiles, ranging from next-generation of clinically proven antibody drugs with significantly improved attributes to antibodies against novel targets. Abmaxis collaborates with corporate partners who have proprietary targets or antibodies that require humanization and engineering. Abmaxis has nine collaborations thus far and continues to seek corporate partnering opportunities. For more information, please visit www.abmaxis.com or contact CJ Wang, Vice President of Business Development, at email@example.com or 408-988-6100, x101.
CONTACT: Shirley Clayton, Chief Executive Officer of Abmaxis, Inc.,+1-408-988-6100, ext. 130, or firstname.lastname@example.org